ADUHELM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ADUHELM (ADUHELM).
Aducanumab is a human monoclonal antibody that selectively binds to aggregated soluble and insoluble forms of amyloid beta, thereby reducing amyloid plaque deposition in the brain.
| Metabolism | Aducanumab is a monoclonal antibody; it is expected to be degraded into small peptides and amino acids via catabolic pathways, similar to endogenous IgG. No specific cytochrome P450 enzymes are involved. |
| Excretion | ADUHELM is eliminated primarily via catabolism into small peptides and amino acids. No renal or biliary excretion of intact monoclonal antibody is expected. Clearance is via the reticuloendothelial system; approximately 97% is metabolized, with <3% excreted as intact antibody in urine. |
| Half-life | Terminal elimination half-life is approximately 26 days (range 19–34 days), supporting monthly intravenous dosing. The long half-life reflects the slow clearance of IgG1 monoclonal antibodies. |
| Protein binding | Approximately 99% bound, primarily to endogenous IgG (via FcRn binding) and other plasma proteins; specific binding proteins include FcRn. |
| Volume of Distribution | Volume of distribution is approximately 6.8 L (central compartment), equivalent to plasma volume; does not distribute extensively into tissues due to large molecular size. In L/kg: ~0.1 L/kg for a 70 kg patient. |
| Bioavailability | Intravenous administration results in 100% bioavailability. No subcutaneous or oral formulation is available; thus no bioavailability for other routes. |
| Onset of Action | Subcutaneous administration not applicable; intravenous infusion: clinical effects on amyloid plaque reduction are observed as early as 6 months, but cognitive benefit may take 12–18 months. |
| Duration of Action | After a single IV infusion, drug levels persist for weeks; weekly dosing maintains steady state. Clinical effect duration is continuous with ongoing treatment; effects wane over months after discontinuation. |
10 mg/kg intravenous infusion over approximately one hour, once every four weeks. Dosing initiation requires a titration schedule: first three doses at 1 mg/kg, fourth dose at 3 mg/kg, fifth dose at 6 mg/kg, and subsequent doses at 10 mg/kg.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (eGFR <30 mL/min/1.73 m²) or end-stage renal disease. |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment. |
| Pediatric use | Safety and efficacy have not been established in pediatric patients. No recommended dosing available. |
| Geriatric use | No specific dose adjustment recommended for elderly patients. Clinical studies included patients aged 65 years and older; no overall differences in safety or efficacy observed. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ADUHELM (ADUHELM).
| Breastfeeding | No data on presence in human milk, effects on breastfed infant, or effects on milk production. Aducanumab is a large IgG molecule; likely excreted into milk in low amounts. M/P ratio unknown. Consider developmental and health benefits of breastfeeding along with mother's clinical need. |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. Based on mechanism of action (anti-amyloid beta monoclonal antibody), potential for fetal harm is unknown. No animal reproductive studies available. Use only if benefit outweighs potential risk. |
■ FDA Black Box Warning
WARNING: AMYLOID-RELATED IMAGING ABNORMALITIES (ARIA). Aducanumab can cause ARIA, including ARIA-E (edema/effusion) and ARIA-H (hemorrhage/hemosiderin deposition), which can be serious and life-threatening. ARIA generally occurs within the first 8 doses. Monitoring with MRI is required prior to and during treatment.
| Serious Effects |
["Known hypersensitivity to aducanumab or any excipients of ADUHELM"]
| Precautions | ["Amyloid-related imaging abnormalities (ARIA), including ARIA-E and ARIA-H","Hypersensitivity reactions including angioedema and urticaria","Risk of seizures (reported in clinical trials)","Concomitant use of antithrombotic medications may increase risk of intracranial hemorrhage"] |
| Food/Dietary | No specific food interactions reported. Patients should maintain a balanced diet as part of overall health management. Avoid grapefruit juice if taking other medications metabolized by CYP3A4, though aducanumab is not metabolized by CYP enzymes. |
Loading safety data…
| Fetal Monitoring |
| Monitor for infusion reactions (hypotension, hypoxia, dyspnea) during administration. Serial clinical assessments for ARIA (amyloid-related imaging abnormalities) via MRI as per standard monitoring. No specific fetal monitoring required; consider ultrasound if clinical concern. |
| Fertility Effects | No data on effects of aducanumab on human fertility. Animal studies not available; no known impact on fertility based on mechanism. |
| Clinical Pearls | ADUHELM (aducanumab-avwa) is a monoclonal antibody targeting aggregated forms of beta-amyloid. It is indicated for Alzheimer disease. Confirmation of amyloid beta pathology via PET or CSF is required before initiation. Titration over 6-8 months is mandatory to reduce risk of amyloid-related imaging abnormalities (ARIA). Monitor for ARIA with MRI prior to the 7th and 12th infusions; suspend dosing if ARIA is detected. Adverse effects include ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposition). Coadministration with anticoagulants may increase risk of ARIA-H. Assess for hypersensitivity reactions. No specific reversal agent is available. |
| Patient Advice | This drug is for patients with mild cognitive impairment or mild Alzheimer disease confirmed by amyloid PET or CSF testing. · Treatment requires intravenous infusion every 4 weeks, with dose titration over at least 6 months. · MRI scans are needed before and during treatment to monitor for brain swelling or small bleeds (ARIA). · Tell your doctor immediately if you experience headache, confusion, dizziness, vision changes, nausea, or seizures. · Avoid blood thinners like warfarin, apixaban, or rivaroxaban unless prescribed; they may increase bleeding risk. · Do not drive or operate heavy machinery if you experience dizziness or visual disturbances. · Report any signs of allergic reaction such as rash, itching, or difficulty breathing. · Store vials in refrigerator and protect from light; do not freeze or shake. |